Latest Commercial Expansion News

Iondrive appoints ex-BHP innovation chief Dr Grant Caffery as CEO, signalling a pivot from development to commercial scale-up following strong rare earth recovery results and a US$15 million Oklahoma funding pathway.

Klevo Rewards has successfully completed a 14-day commercial trial of its stablecoin transaction platform, generating approximately USD 1.22 million in gross revenue and validating its payment capabilities.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

HitIQ Limited attributes recent share price and volume spikes to a recent $1.4 million private placement and investor buying, denying any undisclosed material information.

ClearVue Technologies has earned three international certifications for its Gen 3 Vision Glass, confirming its photovoltaic performance, safety, and durability across multiple product variants.

Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.